Biosimilars Market Size, Share & Demand Trends by 2034

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Biosimilars Market Size Analysis

Global Biosimilars Market Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Monoclonal Antibodies
  1. By Value
3. Granulocyte Colony-Stimulating Factors
  1. By Value
4. Erythropoiesis-Stimulating Agents
  1. By Value
5. Insulin Analogs
  1. By Value
6. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Oncology
  1. By Value
3. Autoimmune & Inflammatory Diseases
  1. By Value
4. Diabetes
  1. By Value
5. Blood Disorders
  1. By Value
6. Ophthalmology
  1. By Value
7. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Drug Stores and Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value

North America Market Analysis

Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Monoclonal Antibodies
  1. By Value
3. Granulocyte Colony-Stimulating Factors
  1. By Value
4. Erythropoiesis-Stimulating Agents
  1. By Value
5. Insulin Analogs
  1. By Value
6. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Oncology
  1. By Value
3. Autoimmune & Inflammatory Diseases
  1. By Value
4. Diabetes
  1. By Value
5. Blood Disorders
  1. By Value
6. Ophthalmology
  1. By Value
7. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Drug Stores and Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
U.S.
1. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Monoclonal Antibodies
    1. By Value
  3. Granulocyte Colony-Stimulating Factors
    1. By Value
  4. Erythropoiesis-Stimulating Agents
    1. By Value
  5. Insulin Analogs
    1. By Value
  6. Others
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Oncology
    1. By Value
  3. Autoimmune & Inflammatory Diseases
    1. By Value
  4. Diabetes
    1. By Value
  5. Blood Disorders
    1. By Value
  6. Ophthalmology
    1. By Value
  7. Others
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Drug Stores and Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
Canada

Europe Market Analysis

Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Monoclonal Antibodies
  1. By Value
3. Granulocyte Colony-Stimulating Factors
  1. By Value
4. Erythropoiesis-Stimulating Agents
  1. By Value
5. Insulin Analogs
  1. By Value
6. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Oncology
  1. By Value
3. Autoimmune & Inflammatory Diseases
  1. By Value
4. Diabetes
  1. By Value
5. Blood Disorders
  1. By Value
6. Ophthalmology
  1. By Value
7. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Drug Stores and Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
U.K.
1. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Monoclonal Antibodies
    1. By Value
  3. Granulocyte Colony-Stimulating Factors
    1. By Value
  4. Erythropoiesis-Stimulating Agents
    1. By Value
  5. Insulin Analogs
    1. By Value
  6. Others
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Oncology
    1. By Value
  3. Autoimmune & Inflammatory Diseases
    1. By Value
  4. Diabetes
    1. By Value
  5. Blood Disorders
    1. By Value
  6. Ophthalmology
    1. By Value
  7. Others
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Drug Stores and Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Monoclonal Antibodies
  1. By Value
3. Granulocyte Colony-Stimulating Factors
  1. By Value
4. Erythropoiesis-Stimulating Agents
  1. By Value
5. Insulin Analogs
  1. By Value
6. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Oncology
  1. By Value
3. Autoimmune & Inflammatory Diseases
  1. By Value
4. Diabetes
  1. By Value
5. Blood Disorders
  1. By Value
6. Ophthalmology
  1. By Value
7. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Drug Stores and Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
China
1. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Monoclonal Antibodies
    1. By Value
  3. Granulocyte Colony-Stimulating Factors
    1. By Value
  4. Erythropoiesis-Stimulating Agents
    1. By Value
  5. Insulin Analogs
    1. By Value
  6. Others
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Oncology
    1. By Value
  3. Autoimmune & Inflammatory Diseases
    1. By Value
  4. Diabetes
    1. By Value
  5. Blood Disorders
    1. By Value
  6. Ophthalmology
    1. By Value
  7. Others
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Drug Stores and Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Monoclonal Antibodies
  1. By Value
3. Granulocyte Colony-Stimulating Factors
  1. By Value
4. Erythropoiesis-Stimulating Agents
  1. By Value
5. Insulin Analogs
  1. By Value
6. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Oncology
  1. By Value
3. Autoimmune & Inflammatory Diseases
  1. By Value
4. Diabetes
  1. By Value
5. Blood Disorders
  1. By Value
6. Ophthalmology
  1. By Value
7. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Drug Stores and Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
UAE
1. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Monoclonal Antibodies
    1. By Value
  3. Granulocyte Colony-Stimulating Factors
    1. By Value
  4. Erythropoiesis-Stimulating Agents
    1. By Value
  5. Insulin Analogs
    1. By Value
  6. Others
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Oncology
    1. By Value
  3. Autoimmune & Inflammatory Diseases
    1. By Value
  4. Diabetes
    1. By Value
  5. Blood Disorders
    1. By Value
  6. Ophthalmology
    1. By Value
  7. Others
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Drug Stores and Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
The rest of MEA

LATAM Market Analysis

Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Monoclonal Antibodies
  1. By Value
3. Granulocyte Colony-Stimulating Factors
  1. By Value
4. Erythropoiesis-Stimulating Agents
  1. By Value
5. Insulin Analogs
  1. By Value
6. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Oncology
  1. By Value
3. Autoimmune & Inflammatory Diseases
  1. By Value
4. Diabetes
  1. By Value
5. Blood Disorders
  1. By Value
6. Ophthalmology
  1. By Value
7. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Drug Stores and Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
Brazil
1. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Monoclonal Antibodies
    1. By Value
  3. Granulocyte Colony-Stimulating Factors
    1. By Value
  4. Erythropoiesis-Stimulating Agents
    1. By Value
  5. Insulin Analogs
    1. By Value
  6. Others
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Oncology
    1. By Value
  3. Autoimmune & Inflammatory Diseases
    1. By Value
  4. Diabetes
    1. By Value
  5. Blood Disorders
    1. By Value
  6. Ophthalmology
    1. By Value
  7. Others
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Drug Stores and Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Biosimilars Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Biocon
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
CELLTRION INC.
Teva Pharmaceutical Industries Ltd.
Samsung Bioepis
Organon
Pfizer Inc.
Amgen Inc.
Accord BioPharma, Inc.
Shanghai Henlius Biotech, Inc.
Amneal Pharmaceuticals LLC.
Sandoz Group AG
Bio-Thera Solutions, Ltd.
Meitheal Pharmaceuticals
Boehringer Ingelheim
Fresenius Kabi AG
Formycon AG
Tanvex BioPharma Inc.
Alvotech
Biogen
Reddy’s Laboratories Ltd.
Others

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment